Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Down 4.5% – Should You Sell?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s stock price traded down 4.5% during trading on Thursday . The company traded as low as $2.36 and last traded at $2.36. 59,001 shares changed hands during trading, a decline of 36% from the average session volume of 92,016 shares. The stock had previously closed at $2.47.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Oppenheimer lifted their price target on Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Zacks Research cut Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Monday, December 8th. Finally, Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a research note on Saturday, October 11th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $26.50.

Chemomab Therapeutics Stock Down 5.9%

The firm has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $3.61. The firm has a market cap of $13.68 million, a PE ratio of -0.75 and a beta of 0.50.

Institutional Investors Weigh In On Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Virtu Financial LLC lifted its holdings in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,803 shares of the company’s stock after buying an additional 16,358 shares during the period. Virtu Financial LLC owned approximately 0.21% of Chemomab Therapeutics worth $34,000 as of its most recent filing with the Securities and Exchange Commission. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).